Summary of 291-Deguchi-SARS-CoV2

SSBD:database
SSBD:database URL
Title
Fluorescence images of immunostaining analysis of SARS-CoV-2 NP in hepatocytes of bile duct (ibd-LoC) or blood vessel (bv-LoC) at 2 or 6 days post-infection (dpi).
Description
-
Relase date
2023-07-20
Updated date
-
License
CC BY
Kind
Image data based on Experiment
Number of Datasets
8 ( Image datasets: 8, Quantitative data datasets: 0 )
Size of Datasets
5.9 MB ( Image datasets: 5.9 MB, Quantitative data datasets: 0 bytes )

Organism(s)
Homo sapiens
Cell lines(s)
hepatocyte
Gene symbol(s)
NA
Protein name(s)
NA

Datatype
-
Molecular Function (MF)
Biological Process (BP)
viral gene expression, cellular response to virus
Cellular Component (CC)
nucleus
Biological Imaging Method
fluorescence microscopy
T scale
-

Image Acquisition
Experiment type
-
Microscope type
-
Acquisition mode
-
Contrast method
-
Microscope model
-
Detector model
-
Objective model
-
Filter set
-

Related paper(s)

Sayaka Deguchi, Kaori Kosugi, Rina Hashimoto, Ayaka Sakamoto, Masaki Yamamoto, Rafal P Krol, Peter Gee, Ryosuke Negoro, Takeshi Noda, Takuya Yamamoto, Yu-Suke Torisawa, Miki Nagao, Kazuo Takayama (2023) Elucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chips., PNAS nexus, Volume 2, Number 3, pp. pgad029

Published in 2023 Mar (Electronic publication in March 7, 2023, midnight )

(Abstract) SARS-CoV-2 induces severe organ damage not only in the lung but also in the liver, heart, kidney, and intestine. It is known that COVID-19 severity correlates with liver dysfunction, but few studies have investigated the liver pathophysiology in COVID-19 patients. Here, we elucidated liver pathophysiology in COVID-19 patients using organs-on-a-chip technology and clinical analyses. First, we developed liver-on-a-chip (LoC) which recapitulating hepatic functions around the intrahepatic bile duct and blood vessel. We found that hepatic dysfunctions, but not hepatobiliary diseases, were strongly induced by SARS-CoV-2 infection. Next, we evaluated the therapeutic effects of COVID-19 drugs to inhibit viral replication and recover hepatic dysfunctions, and found that the combination of anti-viral and immunosuppressive drugs (Remdesivir and Baricitinib) is effective to treat hepatic dysfunctions caused by SARS-CoV-2 infection. Finally, we analyzed the sera obtained from COVID-19 patients, and revealed that COVID-19 patients, who were positive for serum viral RNA, are likely to become severe and develop hepatic dysfunctions, as compared with COVID-19 patients who were negative for serum viral RNA. We succeeded in modeling the liver pathophysiology of COVID-19 patients using LoC technology and clinical samples.

Contact
Kazuo Takayama , Kyoto University , Center for iPS Cell Research and Application (CiRA)
Contributors


Dataset List of 291-Deguchi-SARS-CoV2

#
Dataset ID
Kind
Size
4D View
SSBD:OMERO
Download BDML
Download Images
# 10781
Dataset Kind Image data
Dataset Size 700.9 KB
4D view
SSBD:OMERO
Download BDML
Download Image data

# 10782
Dataset Kind Image data
Dataset Size 554.2 KB
4D view
SSBD:OMERO
Download BDML
Download Image data

# 10783
Dataset Kind Image data
Dataset Size 680.5 KB
4D view
SSBD:OMERO
Download BDML
Download Image data

# 10784
Dataset Kind Image data
Dataset Size 541.2 KB
4D view
SSBD:OMERO
Download BDML
Download Image data

# 10785
Dataset Kind Image data
Dataset Size 1.5 MB
4D view
SSBD:OMERO
Download BDML
Download Image data

# 10786
Dataset Kind Image data
Dataset Size 926.1 KB
4D view
SSBD:OMERO
Download BDML
Download Image data

# 10787
Dataset Kind Image data
Dataset Size 632.1 KB
4D view
SSBD:OMERO
Download BDML
Download Image data

# 10788
Dataset Kind Image data
Dataset Size 479.7 KB
4D view
SSBD:OMERO
Download BDML
Download Image data